Table 3.
The number of patients with responders or non-responders corresponding to cutoff values of eight serum inflammation indexes, and clinical features
| Response (n) | No response (n) | |
|---|---|---|
| NLR at baseline | ||
| ≤ 1.622 | 7 | 1 |
| > 1.622 | 44 | 11 |
| LMR at baseline | ||
| ≤ 3.173 | 19 | 0 |
| > 3.173 | 32 | 12 |
| PLR at baseline | ||
| ≤ 71.108 | 3 | 0 |
| > 71.108 | 48 | 12 |
| S II at baseline | ||
| ≤ 559.266 | 32 | 12 |
| > 559.266 | 19 | 0 |
| LMR at post treatment of second period | ||
| ≤ 5.987 | 46 | 11 |
| > 5.987 | 6 | 1 |
| LMR at post treatment of third period | ||
| ≤ 3.040 | 28 | 2 |
| > 3.040 | 18 | 8 |
| PLR at post treatment of third period | ||
| ≤ 151.516 | 22 | 10 |
| > 151.516 | 24 | 1 |
| S II at post treatment of second period | ||
| ≤ 174.574 | 9 | 1 |
| > 174.574 | 43 | 11 |
| BMI | ||
| Underweight, | 8 | 1 |
| Normal weight | 36 | 8 |
| Overweight | 8 | 3 |
| ECOG-PS | ||
| 0 | 14 | 5 |
| 1 | 38 | 7 |
| Clinical stage | ||
| II | 15 | 4 |
| III | 26 | 7 |
| IV | 11 | 1 |
| Tumor site | ||
| Upper | 3 | 0 |
| Middle | 22 | 8 |
| Lower | 27 | 4 |